




The relative strengths and weaknesses of Nektar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nektar Therapeutics compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 85% points. The greatest weakness of Nektar Therapeutics is the variable Other Liabilities, reducing the Economic Capital Ratio by 36% points.

The company's Economic Capital Ratio, given in the ranking table, is 398%, being 148% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	1,437,687
Cost of Goods Sold	24,412
Intangible Assets	76,501
Liabilities, Current	82,002
Liabilities, Non-Current	20,734
Other Assets	587,133
Other Compr. Net Income	-4,205
Other Expenses	1,412
Other Liabilities	329,861
Other Net Income	-5,207
Other Revenues	1,193,323
Property and Equipment	48,851
Research and Development	399,536
Selling, General and Administrative Expense	81,443

Output Variable	Value in 1000 USD
Assets	2,150,172
Liabilities	432,597
Expenses	506,803
Revenues	1,193,323
Stockholders Equity	1,717,575
Net Income	681,313
Comprehensive Net Income	679,210
BaseVar	2,146,154
ECR before LimitedLiability	343%
Economic Capital Ratio	398%